SINTX Technologies Inc., an advanced ceramics company focused on medical device innovation, has announced its acquisition of the surgical business assets of SiNAPTIC Holdings, LLC. This strategic move is aimed at expanding SINTX's product portfolio in the $1.3 billion foot and ankle fusion market. The acquisition brings patented implant designs and a seasoned executive team to SINTX, enhancing its capabilities in product development, regulatory strategy, and commercialization. Key members from SiNAPTIC will join SINTX in pivotal roles, including Dr. Bryan Scheer as Chairman of the Clinical Advisory Board. The company plans to leverage its FDA-registered and ISO-certified quality system to streamline regulatory approvals and accelerate the development of disruptive products.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.